Treatment News : HIV Lipo Drug Egrifta Now Available; Financial Assistance Programs Open

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 27, 2011

HIV Lipo Drug Egrifta Now Available; Financial Assistance Programs Open

Egrifta (tesamorelin), the lipodystrophy treatment approved by the U.S. Food and Drug Administration (FDA) late last year, is now officially available to people living with HIV and their health care providers, according to announcements from EMD Serono. To expedite prescriptions and reimbursement, the company also described various services—including patient assistance and co-pay programs—now open to HIV-positive patients who need the drug.

Egrifta was approved by the U.S. Food and Drug Administration (FDA) on November 10, 2010. The drug, requiring once-daily injections, was approved to reduce visceral adipose tissue (VAT)— deep belly fat surrounding the liver, stomach and other abdominal organs—in people living with HIV and experiencing lipodystrophy, a side effect of antiretroviral (ARV) therapy.

Egrifta was developed by Theratechnologies, a company based in Montreal, but is to be sold in the U.S. by Rockland, Massachusetts-based EMD Serono. It is a synthetic growth hormone release factor that acts on pituitary cells in the brain to stimulate growth hormone production, which has been shown to reduce VAT in people with lipodystrophy.

The company tested the drug in two Phase III clinical trials involving 816 HIV-positive adult men and women with lipodystrophy and excess abdominal fat. Of these, 543 patients received Egrifta during a 26-week, placebo-controlled period. In both studies, patients treated with Egrifta experienced greater reductions in VAT—about 15 to 17 percent—as measured by CT scan, compared with patients receiving placebo. Some patients reported improvements in their self-image.

The wholesale acquisition cost (WAP) of Egrifta—the pre-retail price charged by EMD Serono—is $23,900 annually, or $1,964 for a 30-day supply.

Prescriptions for Egrifta will need to be processed through the AXIS Center, a centralized group of prescription specialists contracted by EMD Serono. In addition to prescription processing, the AXIS Center offers in-home or in-office injection training to every new patient through a national network of injection trainers, along with educational kits and 24-hour support. The AXIS Center will also facilitate important financial assistance options, including EMD Serono’s patient assistance and co-pay assistance programs. 

For commercially insured patients with a prescription drug benefit that covers Egrifta, the co-pay assistance program covers up to $2,400 of patients’ out-of-pocket cost over a 12-month period. This can offset up to $200 of their co-pay or coinsurance for up to 12 uses before December 31, 2012, but not more than once every 21 days.

Patients may not use the co-pay assistance program if they receive drug benefits from state or federal health care initiatives (including Medicare or Medicaid). This program is not valid in the Commonwealth of Massachusetts.

EMD Serono’s patient assistance program (PAP) provides free Egrifta for eligible patients who are uninsured or underinsured. Patients must meet other eligibility requirements, including a household income that does not exceed 600 percent of the Federal Poverty Level (FPL), which for one person is currently $10,830. Patients must also have a diagnosis of lipodystrophy and be a resident of the United States.

The PAP, which is being coordinated by the AXIS Center, will provide free Egrifta for one year, and patients will need to reapply if they want to continue receiving the drug.

To start the process, licensed health care providers must fax a Statement of Medical Necessity (SMN)—a detailed prescription—and completed patient authorization form to the AXIS Center at 866-823-9554. SMNs will be provided by the EMD Serono sales team or can be requested by calling the AXIS Center at 877-714-AXIS (2947).

Search: Egrifta, tesamorelin, lipodystrophy, truncal obesity, lipohypertrophy, EMD serono, AXIS Center, patient assistance program, PAP, co-pay assistance program


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (4 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    Newhopenate
    New Hope
    Pennsylvania


    jimmy807
    San Antonio
    Texas


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.